02/03/2020 – AB Science announces a new fundraising of EUR 12.3 million Post navigationPreviousPrevious post:Positive top-line Phase 2B/3 results for masitinib in progressive forms of MSNextNext post:Summary of webcast with Key Opinion Leaders on masitinib Phase 2B/3 results in Progressive Forms of MSRelated PostsBoursorama interview of Alain Moussy, CEO of AB ScienceDecember 23, 2020Capital raise for a total amount of 15 million eurosDecember 21, 2020Results from phase 2B/3 study evaluating masitinib in Alzheimer’s diseaseDecember 18, 2020Masitinib in Alzheimer’s Disease Webcast PresentationDecember 17, 2020Results of the Extraordinary General Shareholders’ Meeting of December 16, 2020December 17, 2020Corrective press release regarding adverse events information from study AB09004December 17, 2020
